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Abstract Triple receptor-negative breast cancers
(TNBCs) generally have poor prognoses because of the
loss of therapeutic targets. As lysophosphatidic acid (LPA)
receptor signaling has been shown to affect breast cancer
initiation and progression, we try to evaluate the potential
roles of LPA receptors in TNBCs. We examined mRNA
and protein expressions of LPA receptors 1-3, using
quantitative real-time PCR and immunohistochemical
analyses in normal (n = 37), benign disease (n = 55), and
breast cancer tissues (n = 82). Carcinomas expressed
higher levels of LPA2 and LPA3 mRNAs (0.17 ± 0.070
and 0.05 ± 0.023, respectively) than did normal breast
tissue (0.13 ± 0.072 and 0.02 ± 0.002, respectively).
Enhanced immunohistochemical staining for LPA2 and
LPA3 protein was also consistently observed in carcino-
mas. The LPA3 overexpression was associated with lymph
node metastases, and absence of estrogen receptor, pro-
gesterone receptors, and human epidermal growth factor
receptor 2 expression. TNBC tissues and cell lines showed
the highest LPA3 expression compared with luminal-type
A and B breast cancers. Suppression of LPA3 by shRNA
did not influence cell growth in breast cancer cells. How-
ever, the migration and invasion of TNBC cells were sig-
nificantly inhibited by LPA3-shRNA or inhibitor, which
had no or less effect on normal and non-TNBC breast cells.
In conclusion, our data indicated that the expression of
LPA receptor 3 was increased in human TNBCs and is
associated with tumor metastatic ability, and this implies
that LPA3 is a potential therapeutic target for the treatment
of TNBCs.
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Introduction
Breast cancer is the most commonly diagnosed cancer, and
the leading cause of cancer-related deaths, in women
worldwide [1]. Cases are usually classified by their
expression of estrogen receptors (ER) progesterone recep-
tors (PR), and human epidermal growth factor-2 receptors
(HER2), which together predict treatment response and
prognosis [2]. Although hormone receptor (HR)? breast
cancers have many effective treatment options, fewer tar-
geted therapies are available for triple receptor-negative
breast cancers (TNBCs). Currently, some progress has been
made in classifying TNBCs into several distinct subtypes
using gene expression profiling analyses, and some kinases
and agents were identified as potential druggable targets [3,
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4], but the therapeutic implications are yet to be elucidated
[5]. Thus, characterization of novel molecular biomarkers
is critically required for the treatment of TNBCs.
Lysophosphatidic acid (LPA) receptors are specific G
protein-coupled receptors binding with LPA, which medi-
ates a variety of biological processes, such as cell prolif-
eration, migration, invasion and differentiation [6]. At least
six LPA receptors (LPA1–6) are currently identified, and
their emerging roles in tumorigenesis have been demon-
strated both in vitro and in vivo [7]. In breast tissue, LPA1
and LPA2 are broadly expressed in either normal or
abnormal mammary epithelial cells, whereas expression
levels of LPA3–6 are more restricted or undetectable, which
may account for the various biological effects of LPA [8–
10]. Overexpression of LPA1 and LPA2 was readily
observed in breast cancers with redundant mediation
functions in multiple endogenous LPA responses, includ-
ing cancer cell growth, metastasis, angiogenesis, and che-
moresistance [8, 11–13]. In contrast, less is known about
the role of LPA3 in breast cancer initiation and progression.
Previous published data showed that LPA3 was higher
expression in poorly differentiated breast cancers than
well-differentiated tumors [14, 15], which suggests that
LPA3 contributes to breast cancer progression.
Although the LPA receptors have been shown to affect
breast cancer initiation and progression, the exact expres-
sion patterns and functions in TNBCs have not been fully
examined. In the present study, we characterized the
expression of LPA1–3 in human normal, benign, and
malignant breast tissues and cell lines, and analyzed cor-
relations with clinical and pathological findings to high-
light the possible roles of LPA receptors in the
development and treatment of TNBCs.
Materials and methods
Patients
Specimens of normal breast (n = 37), mammaries with
benign disease (n = 55), and breast cancer (n = 82) were
collected from the First Affiliated Hospital of Xi’an Jiao-
tong University. This study was approved by the IRB of
Xi’an Jiaotong University School of Medicine. All tissues
were pathologically examined. Written informed consent
forms were obtained from all subjects, and all clinical
investigation had been conducted according to the princi-
ples expressed in the Declaration of Helsinki.
RNA isolation and quantitative real-time PCR
Tissues or cells were lysed in the Qiagen RLT lysis buffer
(Qiagen, USA). RNA was extracted with an RNeasy mini
kit (Qiagen, USA) and reverse transcribed by M-MLV
reverse transcriptase (Invitrogen, USA). Quantitative real-
time PCR was performed on a Bio-Rad iQ5 Real-Time
PCR Detection System (Bio-Rad Laboratories, USA) with
a SYBR Green I Master Mix (TAKARA, Japan). PCRs
were performed in triplicate, and the relative gene
expression was calculated against GAPDH. Primer pairs
used in this study were as follows: GAPDH: F, 50-GA-
AGGTGAAGGTCGGAGT-30/R, 50-GAAGATGGTGATG
GGATTTC-30; LPA1: F, 50-AATCGAGAGGCACATTAC
GG-30/R, 50-GTTGAAAATGGCCCAGAAGA-30; LPA2:
F, 50-TTGTCTTCCTGCTCATGGTG-30/R, 50-TCAGCAT
CTCGGCAAGAGTA-30; LPA3: F, 50-TGCTCATTTTGC
TTGTCTGG-30/R, 50-GCCATACATGTCCTCGTCCT-30.
Immunohistochemistry (IHC) analysis
Formalin-fixed paraffin-embedded sections (5 lm thick) of
the normal breast, breast with benign diseases, and breast
cancers were analyzed by IHC with the primary LPA1–3
antibody (1:100) and a biotin-conjugated secondary anti-
body. For IHC quantification, the sections were analyzed
using Nikon TE2000-s microscope (Melville, USA). Four
randomly selected areas were photographed at 409 mag-
nification using a QimageRetiga 2000R camera (Surrey,
Canada). The integral optical density (IOD) of immuno-
reactivity was calculated using the Image-Pro Plus image
analysis software (Media Cybernetics, USA).
Cell lines and culture
The MCF-10A and MCF-7 cells were obtained from Sa-
gene Inc., (Guangzhou, China), and the MCF-12A, T47D,
MDA-MB-231, and MDA-MB-157 cells were obtained
from ATCC (Manassas, USA). All cell lines were main-
tained in a humidified atmosphere at 37 C with 5 % CO2.
MCF-10A, MCF-12A, and MCF-7 cells were cultured in
DMEM with glutamine, 10 % FBS (Gibco, USA), and
100 lg/mL penicillin/streptomycin (P/S). T47D were cul-
tured in RPMI1640 with glutamine, 10 % FBS (Gibco),
and 100 lg/mL P/S. MDA-MB-231 and MDA-MB-157
cultured in Leibovitz’s L-15 Medium (ATCC, USA) with
10 % FBS (Gibco) and 100 lg/mL P/S.
Western blot analyses
Western blot analyses were conducted using standard
procedures, and proteins were detected using primary
antibodies and fluorescent secondary antibodies (IR-
Dye800CW-conjugated or IRDye680-conjugated anti-spe-
cies IgG, Li-Cor Biosciences, Lincoln, NE, USA). The
fluorescent signals were captured on an Odyssey Infrared
Imaging System (Li-Cor Biosciences) with both 700- and
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800-nm channels. Boxes were manually placed around
each band of interest, and the software returned near-
infrared fluorescent values of raw intensity with back-
ground subtraction (Odyssey 3.0 analytical software, Li-
Cor Biosciences).
shRNA transfection
Six-well plates were seeded with 5 9 104 cells/well in
2 mL media 24 h before transfection; cells were 80–90 %
confluent at transfection. Cells were transfected with LPA3
shRNA (100 pmol/well, Santa Cruz Biotechnology, USA)
using Lipofectamine 2000 Reagent (Life Technologies,
USA) according to the manufacturer’s instruction. After
48 h of transfection, cells were selected using puromycin
for 2 weeks. Stable transductants were pooled.
MTT assays
Cells were seeded at a density of 5 9 103 cells/well in
96-well plates at a final volume of 180 lL in incubation, at
37 C, with 5 % CO2. After different time incubation,
20 lL of 5 mg/mL solution of MTT (Sigma, MO, USA) in
PBS was added to each well, and plates were then incu-
bated for 4 h at 37 C. Reaction crystals were then solu-
bilized in 100 % dimethylsulfoxide (Sigma) 20 lL/well
and shaken for 15 min. Absorbance of each well was
measured on a multidetection microplate reader (BMG
LABTECH, USA) at a wavelength of 570 nm.
Cell migration and invasion Assays
Migration and invasion assays were conducted using
transwell plates with 8-lm pore size membranes (Corning
Inc., USA) as described previously [16]. After incubation
for 4 h (for migration assays) or 24 h (for invasion assays),
cells remaining in the upper side of the filter were removed
with cotton swabs. The cells attached on the lower surface
were fixed and stained using crystal violet and washed with
water. Cells were counted with five high power fields per
membrane, and results were presented as the mean number
of cells migrated per field per membrane. All experiments
were conducted in triplicate.
Statistical analyses
Continuous variables were summarized as means with
standard deviations (SD) across the healthy control, benign
disease, and cancer groups. One-way ANOVA was used to
test the overall difference, and Student’s t test was used to
test the pairwise difference across disease statuses. Corre-
lation between two different groups was tested by Pear-
son’s correlation coefficient. P\ 0.05 was considered
significant. All analyses were performed using SPSS soft-
ware version 19.0 (IBM, USA).
Results
Expression patterns of LPA1–3 in breast tissues
We evaluated mRNA expression of LPA1–3 in normal,
benign, and malignant breast epithelium; mRNA levels
were quantified against GAPDH. As shown in Fig. 1a,
breast tissues predominantly expressed LPA1 and LPA2,
whereas LPA3 expression was weakly but detectable in all
specimens. Similar levels of LPA1 mRNA were detected in
normal, benign, and carcinoma tissues (0.11 ± 0.058 vs.
0.13 ± 0.044 vs. 0.13 ± 0.034, P = 0.789; Fig. 1b).
However, LPA2 mRNA levels in breast cancers were sig-
nificantly higher than that in normal tissue (0.17 ± 0.070
vs. 0.13 ± 0.072, P = 0.0002; Fig. 1c). Although low
levels of LPA3 were observed in all breast tissues, the
cancer tissues exhibited a greater expression of LPA3 than
did normal (0.05 ± 0.023 vs. 0.02 ± 0.002, P\ 0.001) or
benign-disease tissues (0.05 ± 0.023 vs. 0.03 ± 0.002,
P\ 0.001) (Fig. 1d). Notably, LPA3 expression was also
Fig. 1 mRNA expression of LPA receptor 1-3 in breast tissues. a To
determine whether the samples expressed LPA receptors, quantitative
real-time PCR was performed by LPA1, LPA2, and LPA3 primers.
The relative gene expression was calculated against GAPDH. b The
relative LPA1 mRNA expression in normal breast epithelium,
mammary with benign disease, and malignant tissues. c The relative
LPA2 mRNA expression in normal breast epithelium, mammary with
benign disease, and malignant tissues. d The relative LPA3 mRNA
expression in normal breast epithelium, mammary with benign
disease, and malignant tissues. ***P\ 0.001
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greater in benign-disease tissue than in normal tissue
(0.03 ± 0.002 vs. 0.02 ± 0.002, P = 0.009; Fig. 1d).
We also immunohistochemically evaluated expression
of LPA receptor proteins in the same specimens (Fig. 2a).
LPA1–3 was detectable in the cell membrane and cytoplasm
in most specimens (113/119 of LPA1, 116/119 of LPA2,
and 110/119 of LPA3). As with the mRNA expression,
enhanced staining for LPA2 and LPA3 protein was clearly
detected in carcinomas in comparison with normal epi-
thelium or benign-disease tissues (Fig. 2c, d), whereas
LPA1 expression did not differ significantly between dif-
ferent groups (Fig. 2b). Protein immunoreactivity
significant correlated with relative mRNA expression
(r = 0.592, P\ 0.001).
Relationship between LPA1–3 mRNA expression
and clinical parameters in breast cancer patients
Relationships between LPA1–3 mRNA expression and
clinical or pathological findings in 82 cases are presented in
Table 1. LPA1 expression did not correlate with any clin-
ical parameters. Higher expression of LPA2 was seen in
postmenopausal patients (P\ 0.05). The higher-stage
tumors tended to express less LPA2, but not significantly
Fig. 2 Protein levels of LPA receptor 1-3 in different breast tissues. a Immunostains for LPA receptor 1-3 in normal, benign disease and
malignant breast tissue. b–d Quantification of immunostains for LPA receptor 1-3 by IOD analysis. *P\ 0.05; ***P\ 0.001
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(P = 0.095). The expression of LPA3 was associated with
hormonal receptor status and lymph node metastases. ER-,
PR-, or Her2- tumors were more likely to express excess
LPA3 than positive ones. Moreover, patients with lymph
node metastases presented with higher LPA3 expression
than patients without metastases (P\ 0.05).
Higher expression of LPA3 in TNBC tissues
and cell lines
As LPA3 expression in carcinomas strongly correlated with
HR status, we subsequently analyzed the distributions of
LPA3 among different tumor immunophenotypes. Breast
cancer patients were classified as luminal A, luminal B, and
TNBC, based on their expression of ER, PR, Her2, and ki-
67 [17]. LPA3 expression differed significantly among
tumors with different immunophenotypes (P\ 0.001;
Fig. 3a). The highest LPA3 protein level was demonstrated
in the TNBCs whereas similar expressions were found
between luminal A and luminal B carcinomas.
To confirm the expression profiles of LPA3 in TNBCs,
we further detected the mRNA and protein levels of LPA3
in normal mammary epithelial cells and breast cancer cell
lines with different molecular phenotypes. As expected,
breast cancer cell lines (MCF-7, T47D, MDA-MB-231, and
MDA-MB-157) expressed more LPA3 than normal
immortal cells (MCF-10A and MCF-12A), and the highest
expression of LPA3 was detected in the TNBC cells
(MDA-MB-231 and MDA-MB-157) (Fig. 3b, c).
Inhibition of LPA3 by shRNA decreased migration
and invasion of TNBC cells
To further analyze the role of LPA3 in breast tumorigen-
esis, we conducted cell proliferation, migration, and inva-
sion assays of LPA3- and control-shRNA-transfected breast
Table 1 Relationship between
LPA receptors expression and
clinical parameters of breast
cancer
* P\ 0.05; ** P\ 0.01;
*** P\ 0.001
Clinical parameters N (%) LPA1 LPA2 LPA3
Age (years)
\50 41 (50.0) 0.134 ± 0.039 0.173 ± 0.064 0.043 ± 0.020
C50 41 (50.0) 0.133 ± 0.045 0.172 ± 0.065 0.051 ± 0.022
Stage
I 14 (17.0) 0.134 ± 0.047 0.184 ± 0.059 0.047 ± 0.030
II 13 (15.9) 0.141 ± 0.042 0.178 ± 0.058 0.048 ± 0.014
III 20 (24.4) 0.127 ± 0.028 0.173 ± 0.069 0.041 ± 0.016
IV 35 (42.7) 0.134 ± 0.047 0.167 ± 0.066 0.050 ± 0.022
Grade
1 29 (35.4) 0.134 ± 0.036 0.177 ± 0.060 0.040 ± 0.016
2 37 (45.1) 0.136 ± 0.048 0.164 ± 0.071 0.050 ± 0.026
3 16 (19.5) 0.125 ± 0.048 0.184 ± 0.070 0.051 ± 0.017
Tumor size
B2.0 cm 30 (36.6) 0.124 ± 0.036 0.173 ± 0.063 0.049 ± 0.023
2.0–5.0 cm 36 (43.9) 0.143 ± 0.046 0.177 ± 0.068 0.049 ± 0.020
[5.0 cm 16 (19.5) 0.130 ± 0.039 0.163 ± 0.058 0.037 ± 0.019
Menopausal status
Premenopausal 32 (39.0) 0.133 ± 0.043 0.154 ± 0.046* 0.043 ± 0.022
Postmenopausal 50 (61.0) 0.134 ± 0.041 0.185 ± 0.071 0.049 ± 0.021
ER status
Negative 37 (45.1) 0.133 ± 0.045 0.169 ± 0.060 0.057 ± 0.023***
Positive 45 (54.9) 0.134 ± 0.039 0.176 ± 0.067 0.038 ± 0.015
PR status
Negative 43 (52.4) 0.132 ± 0.044 0.180 ± 0.072 0.055 ± 0.023***
Positive 39 (47.6) 0.135 ± 0.040 0.166 ± 0.054 0.037 ± 0.014
Her2 status
Negative 55 (67.1) 0.135 ± 0.043 0.164 ± 0.055 0.051 ± 0.023**
Positive 27 (32.9) 0.131 ± 0.041 0.191 ± 0.077 0.038 ± 0.013
Nodal metastasis
Negative 37 (45.1) 0.132 ± 0.042 0.177 ± 0.064 0.034 ± 0.013***
Positive 45 (54.9) 0.135 ± 0.042 0.170 ± 0.064 0.057 ± 0.021
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epithelial cells, including normal immortal cells MCF-10A,
luminal cells MCF-7, and TNBC cells MDA-MB-231.
LPA3 was effectively down-regulated by shRNA in all
three cell lines (Fig. 4a). Cell proliferation tested by MTT
showed that suppression of LPA3 did not influence cell
growth in all three cell lines (Fig. 4b). However, cells with
LPA3-shRNA migrated significantly less than controls in
MDA-MB-231 cells (Fig. 4c). Although LPA3-shRNA also
reduced migration of MCF-7 cells, the inhibitory capacity
was weaker than in MDA-MB-231 cells (Fig. 4c). We also
assessed the effect of LPA3 knockdown on cellular inva-
sion and revealed LPA3 loss significantly decreased inva-
sion of MDA-MB-231 cells, but had less or no effect on
MCF-10A and MCF-7 cells (Fig. 4d).
Ki16425 dose-dependently suppressed migration
and invasion of TNBC cells
We used Ki16425, an antagonist for LPA1 and LPA3, to
confirm the critical roles of LPA3 in TNBC cells. We first
showed that pre-treating MDA-MB-231 cells with Ki16425
did not influence cell viability (Fig. 5a). We then evaluated
the effects of Ki16425 on migration and invasion of TNBC
cells, using transwell assays. As shown in Fig. 5b, c,
Ki16425 suppressed migration and invasion of MDA-MB-
231 cells in a dose-dependent manner.
Discussion
LPA receptors are expressed by normal mammary epithe-
lial cells, with aberrant expression occurring during breast
cancer initiation and progression [18]. In the present study,
we found abnormal expression of LPA receptors in mam-
mary carcinomas, and that LPA2 and LPA3 expression was
enhanced in breast cancer compared with normal breast
and benign-disease tissues, although the expression level of
LPA1 was not significantly different between each sub-
group. Particularly, we also showed significantly increased
LPA3 expression in the TNBCs compared with other
immunophenotype tumors. Subsequently, function analysis
revealed that inhibition of LPA3 by shRNA or antagonist
dramatically suppressed the migration and invasion ability
of TNBC cells, but had no or less effect on normal or
luminal-type cancer cells, which suggests a role for LPA3
in the pathophysiology of TNBCs.
Expression and function of LPA1 in the breast cancer
have been studied extensively. Overexpression of LPA1 is
Fig. 3 High expression of
LPA3 in TNBCs. a The relative
LPA3 mRNA expression in
breast cancer tissues from
luminal A, luminal B and
TNBC patients. b The relative
LPA3 mRNA expression in six
different breast cell lines was
determined by quantitative real-
time PCR. The results are
presented as the mean ± SD
against GAPDH obtained in
three independent experiments.
c Western blots were used to
detect protein levels of LPA3 in
six breast cell lines.
Quantification of protein was
presented as the mean ± SD of
fluorescent values obtained in
three independent experiments.
Compared to normal mammary
cells, P\ 0.05; compared to
normal mammary cells or non-
TNBC cells, P\ 0.001
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Fig. 4 Inhibition of LPA3
decreased migration and
invasion of TNBC cells.
a Expression of LPA3 was
decreased by shRNA. MCF-
10A, MCF-7, and MDA-MB-
231 cells were transfected with
control and LPA3 shRNA.
Forty-eight hours later, cell
lysates were analyzed by
Western blots with anti-LPA3
antibody. b The effect of LPA3
on breast cancer cells growth, as
measured using the MTT assay.
The results are presented as the
mean ± SD of fold increased to
initiation obtained in 3
independent experiments. c,
d Cell transwell assays were
conducted to investigate the role
of LPA3 on breast cancer cells
migration (c) and invasion (d).
The results are presented as the
mean ± SD of cell number
obtained in three independent
experiments. **P\ 0.01;
***P\ 0.001
Fig. 5 Inactivated LPA3 by
Ki16425 suppressed migration
and invasion of TNBC cells.
a MDA-MB-231 cells were
treated with indicated
concentrations of Ki16428 for
1 h, and then cell viability was
measured using the MTT assay.
The results are presented as the
mean ± SD of fold increased to
initiation obtained in 3
independent experiments. b,
c Migration (b) and invasion
(c) of MDA-MB-231 cells were
inhibited by ki16425. MDA-
MB-231 cells were pretreated
with indicated concentrations of
ki16425 for 1 h and then
transferred to collagen- or
matrigel-coated transwell
chambers for migration and
invasion experiments,
respectively. *P\ 0.05;
**P\ 0.01; ***P\ 0.001
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readily observed in breast cancer cells [19]. Manipulation
of LPA1 level or function could alter the survival and
metastatic ability of breast cancer cells both in vitro and
in vivo [11, 12, 14, 20, 21]. However, in our present
research, LPA1 expression levels did not differ signifi-
cantly between normal and malignant breast tissues. This
inconsistency may result from tumor heterogeneity. In
breast cancer, LPA1 is expressed in many cancer cell lines,
but at various levels. It is most likely that LPA1 higher
expressed in more aggressive cell lines, such as MDA-MB-
231, and lower in less aggressive breast cancer cells, such
as MCF-7 [10, 13, 20, 22, 23]. In accord with cell lines,
LPA1 mRNA was significantly more abundant in advanced
stages of breast cancer compared with noninvasive stage
breast tumors [24]. Moreover, accumulating evidence
indicates that the LPA1 contributes to the metastatic
capability of breast cancers. Higher LPA1 expression is
significantly related to positive node and bone metastases
[11, 12], which implies that LPA1 affects breast cancer
progression. However, some clinical studies found no
major expression pattern for the LPA1 between breast
cancer patients and normal controls [8, 25], which suggests
that LPA1 has no role in breast cancer initiation.
From an evolutionary perspective, tumors can be as
genetically and epigenetically heterogeneous cell popula-
tions, although most human tumors are monoclonal out-
growths descending from single progenitor cells [26, 27].
As tumor progression, genetic and epigenetic alterations
occur in progeny cells. However, changes in LPA1
expression as they affect breast cancer initiation and pro-
gression are barely understood and require additional
exploration.
Although the expression and functions of LPA2 have
been the subject of fewer studies, increased LPA2 expres-
sion has been reported in invasive breast carcinoma [8, 14].
Transgenic mice that overexpress LPA2 showed higher
incidence of mammary tumors with early onset than mice
that overexpress LPA1, which implicates LPA2 in the ini-
tiation of breast cancer [14]. In vitro studies, LPA2 has
been verified to regulate LPA-induced breast cancer cells
proliferation and migration through Erk or RhoA pathway
[23, 28]. Recently, a literature also reported LPA2 involved
in LPA-induced IL-6 and IL-8 expression, which promoted
colony formation and cell survival of TNBCs [29]. Toge-
ther with our findings that LPA2 is more highly expressed
in breast cancer patients, these combined data validate
LPA2 as a potential therapeutic target for drug develop-
ment and evaluation in breast cancer.
As with LPA2, little is known about the expression
patterns of LPA3 in breast cancers. Until recently, Nikolay
et al. indicated that LPA3 was higher expressed in human
breast cancers, and most interesting LPA3 overexpression
was associated with absence of ER and PR [30], which
suggests a function of LPA3 in HR
- carcinomas. Our
studies confirmed that LPA3 was overexpression in ER
-/
PR-/Her2- tumor cells and tissues when compared with
normal breast epithelium and luminal-type cancers. Inhi-
bition of LPA3 significantly decreased migration and
invasion of TNBC cells but did not affect other immuno-
type breast cancers, reflecting on dominant metastatic roles
of LPA3 in TNBCs.
Cancer metastasis is a complex biological event of mul-
tiple steps, one of which is epithelial to mesenchymal tran-
sition (EMT), a prelude to increased cellular motility and
plasticity, which thereby enables cellular invasion [31, 32].
Initial evidence for a possible role of LPA and its receptors in
EMT was derived from experiments in hepatocellular car-
cinoma and ovarian cancer by showing a proline-rich tyro-
sine kinase 2 (PYK2) or periostin (alias osteoblast-specific
factor-2)-induced EMT, upon LPA treatment [33, 34]. In the
breast cancer, Jahn et al. [35] demonstrated that LPA1 is up-
regulated in cells that underwent EMT and consequently led
to an increased responsiveness to LPA after EMT. These
results imply that the LPA receptors contribute to cell EMT.
The roles of different LPA receptors in EMT clearly merit
wider investigation.
As a receptor for LPA, LPA3 can promote cancer pro-
gression. However, the downstream pathways of LPA3 are
rarely elucidated. Currently, evidences indicated that Yes-
associated protein (YAP), a transcriptional factor of Hippo
pathway, is a critical downstream mediatio of LPA3 in
ovarian cancer [36]. Thus, we invested the expression
correlation between LPA3 and YAP protein and found that
tumors with overexpression of LPA3 exhibited week YAP
staining (data not shown). As YAP functions as a breast
tumor suppressor [37], LPA3-YAP pathway may involved
in initiation and progression of breast cancers. Interesting,
another study revealed that loss of YAP expression is
associated with estrogen and PR negativity in breast car-
cinomas [38]. Besides, in transgenic mice model, the ER,
PR, and Her2 were significantly decreased in LPA3 over-
expression mice when compared to wild-type mice [14].
All together, LPA3, YAP, and hormonal receptors may
interact in TNBC pathophysiology. However, the exact
mechanism is unclear and requires further study.
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